Leerink Upgrades Illumina to Outperform | GenomeWeb

NEW YORK (GenomeWeb) – Investment bank Leerink has upgraded Illumina's stock to Outperform from Market Perform, anticipating faster than previously expected adoption of its new sequencing instrument, NovaSeq, based on a recent survey by MEDACorp that Leerink commisioned of 40 NGS labs. Leerink set a 12-month price target for Illumina shares at $195.

The investment bank also raised Illumina's 2018 revenue estimates 3 percent to $3.07 billion and its 2019 revenue estimates to $3.44 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
23
Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants.